Introduction: Sex may influence sarcoidosis clinical phenotype and long-term prognosis, but large cohort data are scarce.
Objectives: To characterize sex-based differences in clinical presentation, pulmonary function, treatment, and outcomes in a multicenter Spanish cohort.
Materials and Methods: Retrospective multicenter analysis from the SARCO-I Spanish pulmonary sarcoidosis cohort, including 765 patients diagnosed according to 1999 WASOG criteria from 13 hospitals. Demographic, clinical, radiological, functional, and comorbidity data were compared between sexes.
Results: Of 765 patients, 323 (42%) were male and 442 (58%) female. Males were diagnosed younger (45 ± 13 vs 50 ± 15 years; p<0.001). Males presented with more advanced radiological disease (Scadding IV: 7.1% vs 4.3%), while females more frequently had Stage 0–I (41.4% vs 33.1%) and cutaneous involvement (33.3% vs 18.0%; p<0.001). At diagnosis, males had worse lung function (FVC% 89.7 ± 19.6 vs 93.4 ± 19.2; p=0.046; FEV1% 85.8 ± 20.5 vs 90.2 ± 19.3; p=0.020). Comorbidity burden was similar between sexes (cardiovascular: 8.4% vs 10.2%, p=0.47; respiratory: 14.2% vs 13.1%, p=0.73). Oral corticosteroid use was similar (51.7% vs 49.8%; p=0.65) and CT progression rates at any timepoint during follow-up were comparable (18.6% vs 15.2%; p=0.25). Despite their milder functional and radiological profile, crude 5-year mortality was higher in females (7.2% vs 3.4%; p=0.034).
Conclusions: Male and female sarcoidosis patients present with distinct phenotypes: males show more advanced radiological and functional impairment, while females present with more cutaneous involvement and milder radiological disease. Despite similar treatment intensity and comorbidity burden, females show higher crude 5-year mortality, consistent with their older age at diagnosis, a recognized independent predictor of sarcoidosis mortality in this cohort. These findings highlight the importance of sex-aware clinical assessment and age-adjusted risk stratification in sarcoidosis.